Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023PRNewsWire • 02/13/23
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape OverviewPRNewsWire • 01/23/23
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian CancerPRNewsWire • 12/06/22
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer PatientsPRNewsWire • 12/01/22
Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT BispecificPRNewsWire • 11/16/22
Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC PatientsPRNewsWire • 11/07/22
Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC PatientsPRNewsWire • 11/07/22
Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022PRNewsWire • 10/06/22